All Insight, Analysis and Views

Physician Views Results: Late-stage confirmation is necessary, but dermatologists enthused by AbbVie's Phase II JAK data in atopic dermatitis

Ref: Physician Views Desk

Tags: Physician Views Poll Results AbbVie Regeneron Sanofi Dermatitis Medical Affairs Clinical Research (R&D)Dupixent upadacitinib

ViewPoints: Celgene’s big swing and miss on mongersen ups the ante on ozanimod

Ref: ViewPoints Desk

Tags: ViewPoints Celgene Irritable Bowel Syndrome FDA Medical Affairs Marketing & Sales Clinical Research (R&D)mongersen ozanimod

ViewPoints: With regulators greasing the wheels, uniQure gets another shot at haemophilia gene therapy

Ref: ViewPoints Desk

Tags: ViewPoints uniQure Spark Therapeutics FDA EMA Regulatory Affairs Clinical Research (R&D)SPK-9001 AMT-061 AMT-060

ViewPoints: Eli Lilly taps CureVac to give cancer vaccines another go

Ref: ViewPoints Desk

Tags: ViewPoints CureVac Lilly Immunisation Licensing Clinical Research (R&D)

Roche: Q3 growth drivers and resistors

Ref: IAV other

Tags: IAV Other Roche Lymphomas Breast Cancer Multiple Sclerosis Bladder Cancer Lung Cancer Corporate Affairs Marketing & Sales Rituxan Herceptin Ocrevus Tecentriq

Friday Five - The week in review

Ref: Friday Five Desk

Tags: Friday Five Medical Affairs Mergers & Acquisitions Regulatory Affairs Clinical Research (R&D) Corporate Affairs Licensing Marketing & Sales

ViewPoints: And so it begins- Gilead's CAR-T approval sets off the cell therapy race

Ref: ViewPoints Desk

Tags: ViewPoints Novartis Gilead United States Lymphomas FDA Regulatory Affairs Marketing & Sales Yescarta Kymriah

ViewPoints: Scangos' Vir lands a huge financing to enable some pharma-like deal-making on a venture budget

Ref: ViewPoints Desk

Tags: ViewPoints Humabs BioMed Visterra Alnylam Vir Biotechnology Viral Infections Influenza Bacterial Infections Mergers & Acquisitions Licensing Clinical Research (R&D)

ViewPoints: Regeneron, Sanofi looking to stay one step ahead of rivals

Ref: ViewPoints Desk

Tags: ViewPoints AnaptysBio Amgen Sanofi Regeneron Galapagos Dermatitis Asthma FDA Medical Affairs Marketing & Sales Clinical Research (R&D)tezepelumab Dupixent

ViewPoints: Will AstraZeneca's decision to cuddle up with Merck & Co. be justified?

Ref: ViewPoints Desk

Tags: ViewPoints AstraZeneca Chi-Med Merck & Co.Breast Cancer Lung Cancer Clinical Research (R&D) Corporate Affairs Regulatory Affairs savolitinib Tagrisso Imfinzi Iressa Keytruda Lynparza